Find promising cancer trials in minutes

Enter a patient's cancer details, such as molecular profile and prior treatments, and TrialFetch will rapidly:

Identify trials precisely matching their information
Sort trials by relevance, and show a custom summary and analysis for each trial

TrialFetch (previously HealthScout) works for advanced/metastatic solid tumors (breast cancer, lung cancer, and 20 other cancer types).

Smart matching engine

Physician-led methodology

Free and non-commercial

Blog post: Head-to-head trial match results

Start here

Enter the patient's cancer details to get matching trials.

How it works

1/Our AI translates the patient's info into a computer-readable format

"...had progression on carbo/taxol/Keytruda..."

Had treatment regimen of:
- Carboplatin (drug class: cytotoxic chemotherapy)
- Paclitaxel (drug class: cytotoxic chemotherapy)
- Pembrolizumab (drug class: PD-1/PD-L1 inhibitor)
Result of regimen: progression

2/This data is used to get a list of matching trials

Trial inclusion criterion:
Progression on regimen containing chemotherapy and PD-1/PD-L1 inhibitor

Regimen must contain:
- ≥1 drug in class: cytotoxic chemotherapy
- ≥1 drug in class: PD-1/PD-L1 inhibitor
Result of regimen must have been: progression

✓ Successful match!

3/Learn about the matching trials and find the ones that are the best fit

In the AI Guide tab, chat with an AI agent that learns about the patient, reviews matching trials, and highlights the most promising options.

Guide

Great — since you’re flexible, I pulled a broad set and focused first on trials most tailored to EGFR exon 20 insertion NSCLC after platinum chemotherapy. Below are the ones that look most promising for [Name]. I called out when a study has a close site (≤100 miles from the patient).

Tags in the trials list help you zero in on the best trials. Trials with better tags show up first.

Molecular match Active drug High burden on patient

Our analysis helps identify the most promising drugs and trials:

Zongertinib clinical results

Zongertinib has shown promising preliminary results in ongoing clinical trials. In the Beamion LUNG-1 trial (NCT04886804), a Phase Ia/Ib first-in-human study, zongertinib demonstrated high response rates, particularly among NSCLC patients.

The drug was well tolerated, with low rates of EGFR-mediated adverse events and no discontinuations due to adverse events recorded during the Phase Ib trial. Initial efficacy data from Phase Ib reflected a high objective response rate (ORR) of 74% and a disease control rate (DCR) of 91% [1].

[1] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor, in patients with HER2-positive advanced NSCLC.

About TrialFetch

Who is TrialFetch for?

TrialFetch is for oncologists, patients, caregivers, patient navigators, research coordinators, and anyone trying to identify clinical trial options. Decisions about whether to pursue a trial are complex, so patients should always discuss the results with their oncologist rather than rely on TrialFetch alone.

Who created TrialFetch?

The TrialFetch team is led by Michael Gensheimer MD, a radiation oncologist at Stanford University. Dr. Gensheimer noticed that many of his patients were interested in clinical trials but were struggling to find ones that were a good fit. This inspired him to create TrialFetch. He has been a faculty member at Stanford since 2015 and his deep involvement in clinical trials includes serving as an investigator for phase 1 studies, leading investigator-initiated phase 2 trials, and enrolling patients on large phase 3 trials.

Is the site secure?

Yes, user data is encrypted at all times and TrialFetch lives on the secure Render.com platform. Also, you never need to enter any personal information like date of birth. We do ask for a name for each patient, but you can just use their initials or first name.